Melissa Bradbury

Dr. Melissa Bradbury

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 September 2019 in BJOG: An International Journal of Obstetrics & Gynaecology
Verified
Journal Article
Closed access
PDF file
JRJ Rabasa
J Rabasa
MBMelissa Bradbury
Melissa Bradbury
JSJl Sanchez‐Iglesias
Jl Sanchez‐Iglesias
DGD Guerrero
D Guerrero
CFC Forcada
C Forcada
Antonio Gil-MorenoAntonio Gil-Moreno
Antonio Gil-Moreno

25 April 2021 in Cancers
Verified
Journal Article
Open access
PDF file
MBMelissa Bradbury
Melissa Bradbury
EBEva Borras
Eva Borras
PAPEREZ-BENAVENTE ASUNCION
PEREZ-BENAVENTE ASUNCION
Antonio Gil-MorenoAntonio Gil-Moreno
Antonio Gil-Moreno
ASAnna Santamaria
Anna Santamaria
ESEduard Sabidó
Eduard Sabidó
High-grade serous ovarian cancer (HGSC) remains the most common and deadly subtype of ovarian cancer. It is characterized by its late diagnosis and frequent relapse despite standardized treatment with cytoreductive surgery and platinum-based chemotherapy. The past decade has seen significant advances in the clinical management and molecular understanding of HGSC following the publication of the Cancer Genome Atlas (TCGA) researchers and the introduction of targeted therapies with anti-angiogenic drugs and poly(ADP-ribose) polymerase inhibitors in specific subgroups of patients. We provide a comprehensive review of HGSC, focusing on the most important molecular advances aimed at providing a better understanding of the disease and its response to treatment. We emphasize the role that proteomic technologies are now playing in these two aspects of the disease, through the identification of proteins and their post-translational modifications in ovarian cancer tumors. Finally, we highlight how the integration of proteomics with genomics, exemplified by the work performed by the Clinical Proteomic Tumor Analysis Consortium (CPTAC), can guide the development of new biomarkers and therapeutic targets.

1 January 2022 in Journal of Lower Genital Tract Disease
Verified
Journal Article
Closed access
MBMelissa Bradbury
Melissa Bradbury
JRJordi Rabasa
Jordi Rabasa
MMMaria Teresa Murcia
Maria Teresa Murcia
MDMaria Carme Dinarès
Maria Carme Dinarès
ASAlex Sainz
Alex Sainz
CCCristina Centeno
Cristina Centeno
Objective: The aim was to evaluate the cytology, colposcopic, and pathological factors associated with the absence of high-grade squamous intraepithelial lesion (HSIL)/cervical intraepithelial neoplasia (CIN) 2–3 lesion on loop electrosurgical excision procedure (LEEP) specimens in women with high-grade cytology and/or HSIL/CIN 2–3 biopsy and the risk of disease persistence/recurrence. Materials and Methods: Two-center retrospective study of women undergoing LEEP for high-grade cervical disease between January 2014 and December 2019. Clinical, cytology, colposcopy, and pathology results were evaluated to identify independent predictive factors associated with CIN 1/negative LEEP results. Univariate and multivariate logistic regression models were performed. Follow-up data was evaluated to assess the risk of HSIL/CIN 2–3 persistence/recurrence. Results: Six hundred thirty-nine of 801 women (79.8%) had high-grade cytology and 631 (78.8%) HSIL/CIN 2–3 biopsy. High-risk human papillomavirus test was positive in 98% of women. Loop electrosurgical excision procedure specimen showing CIN 1 or less was found in 27%–31%. Normal/low-grade colposcopy (odds ratio [OR] = 2.17, CI = 1.39–3.39, p = .001) and CIN 1/negative biopsy (OR = 3.25, CI = 2.12–4.99, p < .001) were predictors of negative/CIN 1 LEEP result in women with high-grade cytology. Normal/low-grade cytology (OR = 1.77, CI = 1.19–2.64, p = .005), normal/low-grade colposcopy (OR = 1.66, CI = 1.11–2.49, p = .013), and CIN 2 biopsy (OR = 2.75, CI = 1.73–4.39, p < .001) were predictors in women with HSIL/CIN 2–3 biopsy. Women with a negative/CIN 1 LEEP had lower recurrence/persistence than those with confirmed HSIL/CIN 2–3(1 vs 31, p = .002). Positive endocervical margin (OR = 2.85, CI = 1.10–7.36, p = .03) and high-risk human papillomavirus persistence (OR = 41.3, CI = 16–106.7, p < .01) were predictors of HSIL/CIN 2–3 persistence/recurrence. Conclusions: A CIN 1/negative LEEP specimen in women with high-grade cytology and/or HSIL/CIN 2–3 biopsy is associated with negative/low-grade cytology, normal/low-grade colposcopic findings and CIN 2 biopsy result before treatment. The HSIL/CIN 2–3 disease persistence/recurrence is low when LEEP specimen does not confirm HSIL/CIN 2–3.

13 April 2022 in Cancers
Verified
Journal Article
Open access
PDF file
BDBerta Díaz-Feijoó
Berta Díaz-Feijoó
ÚAÚrsula Acosta
Úrsula Acosta
ATAurelio Angel Torné
Aurelio Angel Torné
BGBlanca Gil-Ibañez
Blanca Gil-Ibañez
AHAlicia Hernández
Alicia Hernández
Antonio Gil-MorenoAntonio Gil-Moreno
Antonio Gil-Moreno
Background: Few studies have evaluated laparoscopic pelvic lymph node (PLN) debulking during staging aortic lymphadenectomy in locally advanced cervical cancer (LACC). It allows us to know the lymph node status and facilitates the action of chemoradiotherapy (CRT) by reducing tumor burden. We evaluated its feasibility and compared the perioperative morbidity and the time to CRT with a control group. Methods: This was a multicenter retrospective study of patients with LACC FIGO stage IIIC1r who were recipients of CRT. We compared two cohorts: group 1, which consisted of 164 patients with surgical staging by laparoscopic aortic lymphadenectomy and PLN debulking, and group 2, which consisted of 111 patients with aortic lymphadenectomy alone. Results: Excision of the bulky nodes was possible in all patients in group 1 except for one. Surgery lasted a median of 82 min longer in group 1 but there was no greater intraoperative bleeding or increased hospital stay. There were no significant differences in intraoperative or postoperative complications between the groups. A significantly shorter time from surgery to the start of RT was observed in group 1. Conclusions: It is feasible to perform laparoscopic PLN debulking in the same procedure as the staging aortic lymphadenectomy in LACC without increasing surgical or postoperative complications and without delaying the start of CRT compared to single aortic lymphadenectomy.

18 July 2022 in European Journal of Surgical Oncology
Verified
Journal Article
Closed access
JSJ.L. Sánchez-Iglesias
J.L. Sánchez-Iglesias
VBVicente Bebia
Vicente Bebia
EGE. Gimenez
E. Gimenez
MHMarta B. Aller Hernández
Marta B. Aller Hernández
MBMelissa Bradbury
Melissa Bradbury
YCY. Cossio-Gil
Y. Cossio-Gil

25 February 2021 in Journal of Lower Genital Tract Disease
Verified
Journal Article
Closed access
MBMelissa Bradbury
Melissa Bradbury
CCCristina Centeno
Cristina Centeno
APAssumpció Pérez-Benavente
Assumpció Pérez-Benavente
AGAntonio Gil-Moreno
Antonio Gil-Moreno
Objectives: The aims of the study were to determine the management strategies offered to women with cervical intraepithelial neoplasia 2 (CIN 2) and the attitude of colposcopists toward its histological diagnosis and to identify the criteria used to select women for conservative management. Methods: Colposcopists working in Spain were invited to participate in an online questionnaire via the Spanish Gynecology and Colposcopy Societies. The survey included 42 questions covering the 3 objectives of the study. One hundred eighty-two colposcopists representing all autonomous regions in Spain responded. The response rate was 26.2%, considering the total number of members. Results: Most colposcopists offer conservative management in selected cases (153/182). The preferred follow-up interval is 6 months (65%), followed by 3–4 months (30%). Observation was considered no longer appropriate after 24 months (29.5%) and 12 months (26.3%), and 24.3% expressed that it depended on women's plan to conceive. During conservative management, 93.9% always perform a cytology, 62.7% human papillomavirus testing, 96.8% colposcopy, 47.9% cervical biopsy, and 28.1% endocervical curettage. Forty-five percent consider that CIN 2 merely represents a misclassified CIN 1 or CIN 3, whereas 46.2% think that CIN 2 lesions are unlikely to regress. Most respondents considered that age older than 40 years (81.3%), human papillomavirus 16 infection (62.1%), HIV infection (76.8%), positive p16 immunostaining (60.2%), a large lesion occupying more than 50% of the cervix (87%), endocervical involvement (91.6%), and previous treatment for CIN 2–3 (77%) are contraindications for conservative management. Conclusions: Management of CIN 2 remains challenging for colposcopists, and a lack of consensus still exists in clinical practice. A better understanding of the natural history of CIN 2 and its clinical outcomes is still necessary to guide clinicians in its management.